Programming tumor evolution with selection gene drives to proactively combat drug resistance
SM Leighow, JA Reynolds, I Sokirniy, S Yao… - Nature …, 2024 - nature.com
Most targeted anticancer therapies fail due to drug resistance evolution. Here we show that
tumor evolution can be reproducibly redirected to engineer therapeutic opportunity …
tumor evolution can be reproducibly redirected to engineer therapeutic opportunity …
[HTML][HTML] Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells
A Sanchez-Martin, P Sanchon-Sanchez… - Biomedicine & …, 2023 - Elsevier
The response of advanced hepatocellular carcinoma (HCC) to pharmacological treatments
is unsatisfactory and heterogeneous. Inactivation of tumor suppressor genes (TSGs) by …
is unsatisfactory and heterogeneous. Inactivation of tumor suppressor genes (TSGs) by …
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced …
N Casagrande, C Borghese, M Avanzo, D Aldinucci - Cells, 2023 - mdpi.com
Classical Hodgkin lymphoma (cHL) is a highly curable disease (70–80%), even though long-
term toxicities, drug resistance, and predicting clinical responses to therapy are major …
term toxicities, drug resistance, and predicting clinical responses to therapy are major …
Overcome Resistance in Doxorubicin-Adapted Hodgkin Lymphoma Cells With Acquired Multidrug Resistance and Improved Immunosuppressive Abilities
N Casagrande, C Borghese, M Avanzo, D Aldinucci - 2023 - preprints.org
Classical Hodgkin lymphoma (cHL) is a highly curable disease (70-80%), even though long-
term toxicities, drug resistance, and predicting clinical responses to therapy are major …
term toxicities, drug resistance, and predicting clinical responses to therapy are major …